摘要
类器官是近年发展起来的基于干细胞或器官前体细胞体外培养而成的3D器官类似物,有研究表明肿瘤类器官能够很好地保留来源肿瘤的基因型和组织学特性。目前包括肺癌、肝癌、结直肠癌、乳腺癌、等在内的肿瘤类器官都表现出了与临床效果相似的药物敏感性,在临床前药物研究中也体现了与基因型相关的药物预测潜力,是极具潜力的抗肿瘤药物新模型。本文综述了类器官技术的发展现状、肿瘤类器官在药物研究方面的应用,并对比了类器官与其他肿瘤模型的优势和局限,对于促进恶性肿瘤的新药研究及个体化治疗意义重大。
Organoids are in vitro 3 D cell structures derived from stem cells or organ precursor cells,which have been developed in recent years.Studies demonstrated that tumor organoids could accurately mimic the genotypic and histological characteristics of the source tumors.Drug response assays in tumor organoids involving lung cancer,liver cancer,colorectal cancer,and breast cancer,have shown similar results to those in clinical practice.In addition,organoids have revealed potential in predicting drug effects that were related to genetic mutations in tumors.Therefore,they are now regarded as a promising model for anti-tumor drug screening and evaluation.This paper summarized the development of organoid culture technology and the application of tumor organoids in drug research,and compared the advantages and limitations of organoids and those of other tumor research models,providing a significant contribution to promoting the research of drug discovery and individualized treatment of malignant tumors.
作者
李娇
李睿
赵海洋
吴梦春
李莉
张翼冠
谭蕊蓉
赵军宁
Li Jiao;Li Rui;Zhao Haiyang;Wu Mengchun;Li Li;Zhang Yiguan;Tan Ruirong;Zhao Junning(West China School of Pharmacy,Sichuan University,Chengdu 610041;Sichuan Provincial Engineering Technology Research Center for Dao-di Herb System Development,Sichuan Provincial Engineering Research Center for Formation Principle and Quality Evaluation of Dao-di Herbs,Sichuan Provincial Key Laboratory of Translational Chinese Medicine,Key Research Office for Biological Evaluation of Traditional Chinese Medicine Quality of National Administration of Traditional Chinese Medicine,Sichuan Institute for Translational Chinese Medicine,Sichuan Academy of Chinese Medical Sciences,Chengdu 610041;Radiotherapy Center,Sichuan Cancer Hospital,The Affiliated Cancer Hospital of School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041;School of Life Science and Engineering,Southwest University of Science and Technology,Mianyang 621010;College of Food and Biological Engineering,Chengdu University,Chengdu 610106)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2022年第5期200-208,共9页
Pharmacology and Clinics of Chinese Materia Medica
基金
四川省省级科研院所基本科研业务费项目(编号:A-2022N-Z-2)
四川省中医药科学院科研项目(编号:QNCJRSC2022-9)
电子科技大学四川省肿瘤医院"肿瘤医工创新基金"项目(编号:ZYGX2021YGCX020)
四川省肿瘤医院优秀青年基金项目(编号:YB2021035)。
